{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-126599","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.716562+00:00","generated_at":"2026-06-07T11:13:44.887929+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cara discontinues AD program after oral difelikefalin fails Phase 3 KIND 1 study","bullets":["Oral difelikefalin as adjunct to TCS did not meet primary endpoint vs TCS alone in 287-patient trial.","Cara discontinues clinical program for pruritus in atopic dermatitis.","Late-stage programs for notalgia paresthetica and advanced CKD continue; data readouts expected 2H24.","Cara expects ~$100M cash at year-end 2023, including $20M milestone payment from HealthCare Royalty."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-126599","json":"https://secwatch.observer/filing/0001104659-23-126599.json","markdown":"https://secwatch.observer/filing/0001104659-23-126599.md","text":"https://secwatch.observer/filing/0001104659-23-126599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923126599/0001104659-23-126599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923126599/tm2333104d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:13:44.887929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}